Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Data Supplement
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hee Kang, J.
Right arrow Articles by Grodstein, F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hee Kang, J.
Right arrow Articles by Grodstein, F.
Related Collections
Right arrow All Cognitive Disorders/Dementia
Right arrow Alzheimer's disease
Right arrow Cognitive aging
Right arrow All epidemiology
Right arrow Risk factors in epidemiology

Neurology 2003;60:1591-1597
© 2003 American Academy of Neurology

Regular use of nonsteroidal anti-inflammatory drugs and cognitive function in aging women

Jae Hee Kang, ScD and Francine Grodstein, ScD

From Channing Lab (Drs. Kang and Grodstein), Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School; and the Department of Epidemiology (Dr. Grodstein), Harvard School of Public Health, Boston, MA.

Address correspondence and reprint requests to Dr. Jae Hee Kang, Channing Lab, 181 Longwood Ave., Boston, MA 02115; e-mail: nhjhk{at}channing.harvard.edu

Objective: To examine the relationship of nonsteroidal anti-inflammatory drug (NSAID) use and cognitive decline in young-old women.

Methods: The authors prospectively studied 16,128 Nurses’ Health Study participants, aged 70 to 81 years at baseline, who provided information on NSAID use and potential confounders in biennial questionnaires from 1976 through 1998. From 1995 through 2001, we administered, by telephone, six tests of cognitive function, including the Telephone Interview of Cognitive Status (TICS). Second interviews were begun 2 years later and completed on 13,255 women to date. The authors used multiple logistic regression to estimate relative risks (RR) of low baseline scores (defined as the bottom 10%) and substantial decline (worst 10%).

Results: Compared to never users, the RR was 0.75 (95% CI 0.59, 0.96) for a low baseline TICS score with current aspirin use of 15+ years duration, and 0.79 (95% CI 0.62, 1.02) for current use of NSAID (primarily ibuprofen) lasting 8+ years. Results for aspirin users were weaker on other tests, but long-term ibuprofen users had a RR of 0.75 (95% CI 0.56, 1.00) for a low baseline global score (combination of all six tests). The RR for substantial global cognitive decline was 0.93 (95% CI 0.68, 1.26) with long-term aspirin use, and 0.77 (95% CI 0.57, 1.05) with long-term ibuprofen use.

Conclusions: In these young-old women, current, long-term NSAID users, especially of nonaspirin agents, showed reduced odds of low cognitive function and possibly lower rates of substantial cognitive decline over 2 years. Continued follow-up will help determine if associations differ at older ages.




This article has been cited by other articles:


Home page
NeurologyHome page
Z. Arvanitakis, F. Grodstein, J. L. Bienias, J. A. Schneider, R. S. Wilson, J. F. Kelly, D. A. Evans, and D. A. Bennett
Relation of NSAIDs to incident AD, change in cognitive function, and AD pathology
Neurology, June 3, 2008; 70(23): 2219 - 2225.
[Abstract] [Full Text] [PDF]


Home page
Nutr Clin PractHome page
M. H. DeLegge and A. Smoke
Neurodegeneration and Inflammation
Nutr Clin Pract, February 1, 2008; 23(1): 35 - 41.
[Abstract] [Full Text] [PDF]


Home page
Arch Intern MedHome page
F. Grodstein, J. H. Kang, R. J. Glynn, N. R. Cook, and J. M. Gaziano
A Randomized Trial of Beta Carotene Supplementation and Cognitive Function in Men: The Physicians' Health Study II
Arch Intern Med, November 12, 2007; 167(20): 2184 - 2190.
[Abstract] [Full Text] [PDF]


Home page
BMJHome page
J. H. Kang, N. Cook, J. Manson, J. E Buring, and F. Grodstein
Low dose aspirin and cognitive function in the women's health study cognitive cohort
BMJ, May 12, 2007; 334(7601): 987 - 987.
[Abstract] [Full Text] [PDF]


Home page
NeurologyHome page
A. Kalaydjian, P. P. Zandi, K. L. Swartz, W. W. Eaton, and C. Lyketsos
How migraines impact cognitive function: Findings from the Baltimore ECA
Neurology, April 24, 2007; 68(17): 1417 - 1424.
[Abstract] [Full Text] [PDF]


Home page
Am J EpidemiolHome page
A. J. M. de Craen, J. Gussekloo, B. Vrijsen, and R. G. J. Westendorp
Meta-Analysis of Nonsteroidal Antiinflammatory Drug Use and Risk of Dementia
Am. J. Epidemiol., January 15, 2005; 161(2): 114 - 120.
[Abstract] [Full Text] [PDF]


Home page
BMJHome page
G. Logroscino, J. H. Kang, and F. Grodstein
Prospective study of type 2 diabetes and cognitive decline in women aged 70-81 years
BMJ, March 6, 2004; 328(7439): 548.
[Abstract] [Full Text] [PDF]


Home page
BMJHome page
Minerva
BMJ, June 5, 2003; 326(7401): 1274 - 1274.
[Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2003 by AAN Enterprises, Inc.